The 23rd Awaji International Forum on Infection and Immunity
Advanced Search

Session Details

Symposium

[S05]Symposium 5

Thu. Sep 11, 2025 3:40 PM - 6:00 PM JST
Thu. Sep 11, 2025 6:40 AM - 9:00 AM UTC
Lecture Hall(Main Hall)
Chair (s):Shinjiro Hamano(Nagasaki Univ, Japan)
3:40 PM - 3:50 PM JST(6:40 AM - 6:50 AM UTC)

[S05-01]Public-Private Partnerships in Advancing Vaccines

○Hayato Urabe1 (1. Global Health Innovative Technology Fund (Japan))
Comment()
3:50 PM - 4:10 PM JST(6:50 AM - 7:10 AM UTC)

[S05-02]Outlook for vaccination and global elimination of leishmaniasis

○Greg Matlashewski1 (1. McGill Univ, Canada (Canada))
Comment()
4:10 PM - 4:30 PM JST(7:10 AM - 7:30 AM UTC)

[S05-03]Development of LST antigen and its use as a surrogate marker for immunogenicity

Sreenivas Gannavaram1, Kamaleshwar P Singh2, Swarnendu Kaviraj2, Shinjiro Hamano3, Greg Matlashewski4, Hira L Nakhasi1, Sanjay Singh2, ○Abhay R Satoskar4,5 (1. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA. (United States of America), 2. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India, (India), 3. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan. The Joint Usage/Research Center on Tropical Disease, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan. (Japan), 4. Department of Microbiology and Immunology, McGill University, Montreal, Canada. (Canada), 5. Department of Pathology and Microbiology, Ohio State University, Columbus, OH, USA. (United States of America))
Comment()
4:30 PM - 4:50 PM JST(7:30 AM - 7:50 AM UTC)

[S05-04]Advancement in Leishmania vaccination development and its role in global elimination of leishmaniasis

○Hira Nakhasi1 (1. Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA (United States of America))
Comment()
4:50 PM - 5:10 PM JST(7:50 AM - 8:10 AM UTC)

[S05-05]Value of a Controlled Human Infection Model to Test the Efficacy of Leishmania Vaccines

Eva A. Iniguez1, Tiago D. Serafim1, Jesus G. Valenzuela1, Josh R. Lacsina1, ○Shaden Kamhawi1 (1. National Institutes of Health (United States of America))
Comment()
5:10 PM - 5:30 PM JST(8:10 AM - 8:30 AM UTC)

[S05-06]Progress in creating effective strategies for the control and elimination of leishmaniasis.

Kamaleshwar P Singh1, Swarnendu Kaviraj1, Sreenivas Gannavaram2, Abhay R Satoskar3, Shaden Kamhawi4, Shinjiro Hamano5, Greg Matlashewski6, Hira L Nakhasi 7, ○Sanjay Singh8 (1. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India (India), 2. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA (United States of America), 3. Department of Pathology and Microbiology, Ohio State University, Columbus, OH , USA (United States of America), 4. Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland, 20852, USA (United States of America), 5. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan. (Japan), 6. Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada (Canada), 7. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA (United States of America), 8. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India, (India))
Comment()
5:30 PM - 5:50 PM JST(8:30 AM - 8:50 AM UTC)

[S05-07]Leishmania vaccine: Upcoming clinical trials, key challenges to overcome, and global partnerships

○Kawsar Talaat1 (1. Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health (United States of America))
Comment()
Back to Category List